Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues near the N-term of human SHP-2 was used as immunogen. This antibody is predicted to detect splice isoforms 2 and 3 based on sequence analysis.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
SHP-2 (also called PTP2C, SH-PTP2, PTP1D, SH-PTP3, Syp and PTPN11) is a protein tyrosine phosphatase (PTP) expressed in most cell types (unlike SHP-1), (1). SHP-2 is involved in t the signal transduction stimulated by EGF, PDGF and Insulin. After cell stimulation, SHP-2 (as well as SHP-1), translocates from cytosol to the plasma membrane and binds to tyrosine-phosphorylated receptors through their SH2 domains, becoming activated in the process (2). When phosphorylated, SHP-2 has been shown to bind Grb2, EGFR, PDGFR, IRS-1 via its SH2 domain (3). Overexpression of SHP-2 leads to Juvenile Myelo-monocytic Leukemia and Noonan syndrome (4-5).
Related Pathway
EGFR1 Signaling Pathway
Hemostasis
Jak-STAT signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
